This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Quest Diagnostics files reply in support of dismissing US antitrust claims over allergy testing, treatment

( July 30, 2021, 22:31 GMT | Official Statement) -- MLex Summary: Quest Diagnostic told a US judge that plaintiffs bringing antitrust claims have conceded their alleged single “relevant market” includes two separate services that aren't substitutes and that they didn't allege “single firm” conduct by Quest, and don't even attempt to defend their monopolization and attempted monopolization claims. Quest filed a reply in support of its motion to dismiss claims that it illegally monopolizes the market for allergy testing and immunotherapy.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections